We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Sequencing Chip Screens for Parkinson's Disease

By Biotechdaily staff writers
Posted on 05 Mar 2007
Scientists have developed a cost-effective diagnostic test for Parkinson's disease (PD), which will also assist researchers to understand the genetic basis of PD and to undertake large-scale studies to identify the genes that cause this debilitating condition. More...

Currently there is no specific PD diagnostic test and doctors rely on their observations to make a diagnosis, which means some patients may not be prescribed the most suitable medication and around 15% of those diagnosed may actually be suffering from something else.
The Howard Florey Institute (Melbourne, Australia) research leader, Dr Justin Rubio, has created a ‘gene-sequencing chip' that screens 17 genes in all, including the six known Parkinson's disease genes plus some other suspects in one simple test, at a reasonable cost. Dr. Rubio said the gene-sequencing chip would allow for routine testing of people suspected of having Parkinson's disease.
"Around 100,000 Australians have Parkinson's disease but few have had DNA testing for the known genes that cause the disease due to the prohibitive cost,” Dr Rubio said. "In addition to providing a genetic diagnosis it is hoped that our chip will eventually be able to pinpoint genetic changes that help to predict a person's prognosis and even the treatment that best suits them.”
Dr Rubio added, "As the test is relatively cheap and only involves collecting a sample of blood or saliva, it could also be made available to the patient's relatives and those at risk of developing PD. In addition to being a diagnostic tool, this low-cost chip will allow researchers to undertake an Australia-wide gene-mapping study to identify further genes that are involved in PD. More genetic information will deepen our understanding of PD and enable researchers to work towards ways of preventing and treating the disease. The successful implementation of this technology could also lead to genetic testing for other diseases.”
Dr Rubio plans to test the chip on DNA samples from 400 people with PD who were recruited from Victoria and Tasmania (both in Australia), and this project involves collaborators from hospitals and research institutes in both states.
Using the gene-sequencing chip, Dr Rubio and his collaborators now hope to extend the ‘Gene Discovery' project to all Australian states to determine the genetic basis of PD.


Related Links:
Howard Florey Institute

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Total Laboratory Automation Solution
SATLARS Mini T8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.